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Introduction
The dementia syndromes associated with 
neurodegeneration present with progressive 
cognitive decline that may involve amnesia, 
aphasia, apraxia, agnosia and often 
psychological and psychiatric symptoms1. 
7 million people suffer from dementia in 
Europe2. In Malta, the prevalence rate for 2015 
is projected to be 1.25%, affecting a total of 
4892 people from different age groups3.    
Identifying the aetiology of dementia and 
hence making a speciﬁc dementia diagnosis 
(Alzheimer’s disease, vascular dementia 
etc.) is critical, because this inﬂuences the 
management of dementia and the associated 
psychiatric symptoms. It is challenging to 
make a deﬁnitive diagnosis because there is 
no single and authoritative diagnostic test 
to identify most dementia syndromes.4 In 
addition, it has been disputed whether the 
underlying pathology can be reliably elicited 
in living patients after a multi-centre post-
mortem study in the UK found a mismatch 
between the diagnosis of the dementia type 
and the actual neuropathology present in the 
brain.5  
Secondary causes of dementia include 
traumatic brain lesions, frontotemporal 
dementia, subcortical dementia and focal 
dementia. Frontotemporal dementia tends to 
present with marked behavioural rather than 
memory problems.Examples of subcortical 
dementia and focal dementia are Parkinson’s 
disease dementia and progressive aphasia 
respectively. 
A study by the Medical Research Council 
UK investigated the prevalence of a spectrum 
of psychological and psychiatric symptoms in 
patients with dementia.9 An example of the 
overlap between dementia and psychiatric or 
psychological symptoms such as irritability, 
hallucinations, agitation and anxiety are found 
in Table 1. 
The presence of these symptoms was much 
more marked in patients with dementia rather 
than patients without dementia. 
Irritability, hallucinations, agitation and 
anxiety can give rise to difﬁcult behaviour 
in patients with dementia and this must be 
managed accordingly because the welfare of 
the patients themselves and also their carers 
and co-residents in nursing homes could be 
affected. 
The National Institute for Clinical 
Excellence (NICE) has issued guidance for the 
management of non-cognitive symptoms and 
challenging behaviour in dementia. The guidance 
has deﬁned these symptoms as illustrated in 
Table 3.
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Dementia is an age-related progressive syndrome that often presents 
with psychiatric symptoms such as hallucinations, aggression 
and agitation. The management of such symptoms in dementia 
is particularly important when it puts the patients themselves 
and their carers at risk. The NICE guidance for pharmacologically 
managing psychiatric symptoms in dementia and the evidence base 
is summarised with particular focus on antipsychotic drug use. 
Alternative approaches to psychiatric symptoms in dementia are 
brieﬂy discussed as a substitute for antipsychotic use. 
Educational aims
s  To brieﬂy review the different dementia syndromes and some associated psychiatric 
symptoms 
s  4O SUMMARISE .)#% GUIDELINES ON THE MANAGEMENT OF CHALLENGING PSYCHIATRIC BEHAVIOUR 
in dementia and the evidence base behind the guidance 
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Antipsychotic drugs
ŶƟƉƐǇĐŚŽƟĐĚƌƵŐƐƐŚŽƵůĚŶŽƚďĞƵƐĞĚ
ĨŽƌŶŽŶͲĐŽŐŶŝƟǀĞƐǇŵƉƚŽŵƐƚŚĂƚĂƌĞmild 
to moderateŝŶ>ĞǁǇďŽĚǇĚĞŵĞŶƟĂĚƵĞ
ƚŽƚŚĞƌŝƐŬŽĨƐĞǀĞƌĞĂĚǀĞƌƐĞĞīĞĐƚƐ͘dŚĞǇ
ƐŚŽƵůĚĂůƐŽŶŽƚďĞƵƐĞĚŝŶmild to moderate
ďĞŚĂǀŝŽƵƌĂůƐǇŵƉƚŽŵƐŝŶůǌŚĞŝŵĞƌ Ɛ͛ĚŝƐĞĂƐĞ
ĂŶĚĚĞŵĞŶƟĂŽĨǀĂƐĐƵůĂƌŽƌŵŝǆĞĚŽƌŝŐŝŶ
ĚƵĞƚŽƚŚĞƌŝƐŬŽĨĐĞƌĞďƌŽǀĂƐĐƵůĂƌͲĂƐƐŽĐŝĂƚĞĚ
ŵŽƌďŝĚŝƚǇĂŶĚŵŽƌƚĂůŝƚǇ͘ŶƟƉƐǇĐŚŽƟĐ
ĚƌƵŐƐĐĂŶŚŽǁĞǀĞƌďĞĐŽŶƐŝĚĞƌĞĚŝŶ
ĚĞŵĞŶƟĂƉĂƟĞŶƚǁŚŽĚĞǀĞůŽƉŶŽŶͲĐŽŐŶŝƟǀĞ
ƐǇŵƉƚŽŵƐƐƵĐŚĂƐƉƐǇĐŚŽƐŝƐĂŶĚĂŐŝƚĂƟŽŶ
ƚŚĂƚĂƌĞƐĞǀĞƌĞĂŶĚĚŝƐƚƌĞƐƐŝŶŐ͕ƉƌŽǀŝĚĞĚ
ƚŚĂƚŚĞĂůƚŚĐĂƌĞǁŽƌŬĞƌƐĚŝƐĐƵƐƐƚŚĞƌŝƐŬƐĂŶĚ
ďĞŶĞĮƚƐŽĨĂŶƟƉƐǇĐŚŽƟĐƚƌĞĂƚŵĞŶƚ͘
Table 1: Dementia type in order of decreasing prevalence, 
starting with the most common1,2,6,7,8
Dementia type Prevalence Aetiology
Alzheimer’s disease 60-70% Amyloid deposition and hyper-phosphorylated tau 
which lead to neuronal death; clinical progression 
tends to be gradual
Vascular dementia 32% Neuronal death caused by ischaemic insults in the 
CNS; clinical progression tends to be incremental
Mixed dementia 10-40% A combination of Alzheimer’s disease with cognitive 
decline related to vascular pathology
Lewy body dementia 15% Neuronal death caused by _-synuclein accumulations 
in neurons. The clinical presentation often involves 
Parkinsonian symptoms
Other causes 5% Secondary causes of dementia, frontotemporal 
dementia, subcortical dementia and focal dementia
Table 2: The prevalence of selected psychiatric and psychological symptoms in patients 
with and without dementia, expressed as the percentage prevalence per population9
Symptoms Participants Participants P value
Assessment criteria without dementia  with dementia
 (N=2050) (N=587)
Irritability 12.8  28.8 <0.001
Participant has been more angry or 
irritable lately, interviewer observes 
severe hostility or angry response 
Depression 8.6 20.5 <0.001
Assessed using Cambridge Mental 
Disorders of the Elderly Examination 
depression algorithm
Hallucinations  3.7  15.1 <0.001
Hearing voices; visions; smells 
or gustatory hallucination 
Agitation 3.6  9.0 <0.001
Inappropriate verbal, vocal or motor 
activity; observed restlessness during interview 
Anxiety 6.3  8.9 0.068
Suffering from fear or panic attacks, 
often trembles or interviewer observed 
severe bodily features of anxiety
% Population prevalence
Table 3: Deﬁnitions of non-cognitive symptoms of dementia and challenging behaviour 
as used in the NICE 2011 guidelines10
Non-cognitive symptoms of dementia Challenging behaviour
Hallucinations Aggressive behaviour
Delusions Agitation 
Anxiety Wondering, hoarding
Marked agitation Shouting 
Aggressive behaviour Sexual disinhibition
Practice points 2
Considerations for prescribing 
antipsychotics in dementia10
s  4HE INCREASED RISK OF STROKE HAS TO BE 
justiﬁed by beneﬁts of antipsychotics.
s  #OGNITION HAS TO BE MONITORED AND 
patients switched to other drugs if 
necessary. 
s  #OMORBIDITIES SUCH AS DEPRESSION 
should be considered in the decision to 
start antipsychotics.
s  !NTIPSYCHOTIC DOSE SHOULD BE STARTED AT 
low levels and titrated up. 
s  4HE DURATION OF TREATMENT IS LIMITED TO 
the minimum necessary and should be 
reviewed every three months.
s  )N DEMENTIA WITH ,EWY BODIES 
vigilantly monitor for neuroleptic 
sensitivity reactions which can lead to 
cognitive and functional impairment 
and can even be fatal.
s  !S AN ALTERNATIVE TO ANTIPSYCHOTICS 
the use of AChEIs may be appropriate 
in dementia with Lewy bodies and all 
stages of Alzheimer’s disease but not 
vascular dementia.
Acetylcholinesterase inhibitors
An acetylcholinesterase inhibitor 
(AChEI) can be considered in patients 
with dementia having Lewy bodies that 
have challenging non-cognitive behaviour 
as deﬁned in Table 2. It may also be 
appropriate for Alzheimer’s disease of 
all severities if non-pharmacological 
management is inappropriate or ineffective, 
or if antipsychotic treatment has been 
unsuccessful or cannot be used. AChEIs 
should not be used in vascular dementia 
for psychiatric symptoms unless as part of 
clinical studies.  
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Evidence behind the guidance: 
Pharmaceutical care issues with 
antipsychotics
The main pharmaceutical care issues 
with antipsychotic agents in dementia lie 
with their safety and efﬁcacy.  The main 
risks are the development of neuroleptic 
sensitivity syndrome, risk of stroke and risk 
of death. Neuroleptic sensitivity syndrome 
is characterised by the development of 
adverse effects such as the precipitation 
or aggravation of extrapyramidal symptoms 
and signiﬁcant physical deterioration, and 
possibly death, after antipsychotic drug 
administration.11 Patients with Lewy body 
dementia are particularly sensitive to the 
negative effects of antipsychotics.12 It 
had been suggested that this is linked to 
the Parkinsonian component of Lewy body 
dementia almost a decade ago.13 This is not 
surprising, as it is known that antipsychotics 
that antagonise the dopaminergic system 
can worsen Parkinsonian symptoms that are 
a result of central dopaminergic deﬁcit.14 
The gravity of neuroleptic sensitivity in 
Lewy body dementia becomes apparent 
when considering that it can result in 
or contribute signiﬁcantly to death. One 
study that followed hospitalised patients 
with dementia found that the time from 
antipsychotic administration to death varied 
from 9 days to 12 months at most.6 This 
study provided clinicians with two important 
warnings: the severity of neuroleptic 
sensitivity symptoms may not be related to 
the dose of the antipsychotic or whether it is 
a typical or atypical agent. The consequences 
of antipsychotic prescribing in Lewy body 
dementia could therefore be particularly 
serious, especially considering evidence 
from a randomised double-blind placebo 
controlled trial showing that not only is 
quetiapine not effective in treating agitation 
in dementia but also that quetiapine can 
accelerate cognitive decline.15  The Cochrane 
Dementia and Cognitive Improvement 
Group have shown that risperidone and 
olanzepine modestly reduce aggression and 
risperidone can have a modest beneﬁcial 
effect on psychosis but both are linked to 
signiﬁcantly increased risk of extrapyramidal 
symptoms and cerebrovascular adverse 
effects.15 Another safety concern with the 
use of typical and atypical antipsychotics 
is the increased risk of stroke which can be 
increased between three- and ﬁve-fold.16 
The sum of this evidence suggests that 
commonly used antipsychotics are only 
marginally effective in selected psychiatric 
symptoms such as aggression and agitation 
but signiﬁcantly increase the risk of patient 
harm and death.17 
Alternative management of psychiatric 
symptoms in dementia
Acetylcholinesterase inhibitors were 
found to have a beneﬁcial effect in 
irritability, anxiety and disinhibition.17 
Donepezil and galantamine, for example, 
were found to be of potential beneﬁt in 
severe  Alzheimer’s disease.18 This suggests 
that cholinergic deﬁcits play a role in 
neuropsychiatric symptoms. Although 
memantine (an NMDA receptor antagonist) 
is not clearly mentioned in the NICE 
guidelines for management of non-cognitive 
symptoms in Alzheimer’s disease19, it was 
also found to be beneﬁcial in agitation 
and aggression in Alzheimer’s disease.20 
Despite this evidence for pharmacotherapy, 
it is important not to underestimate the 
role of non-pharmacological interventions. 
Agitation and aggression may be the result 
of pain, loneliness, boredom and depression 
which can be addressed through socialising, 
reminiscence therapy, aromatherapy, music 
therapy, art therapy and multi-sensory 
approaches to name a few.21 Interventions 
involving support and training of nursing 
home staff to change their clinical approach 
and deliver a more ‘person-centered’ 
approach resulted in the reduced prescription 
of antipsychotics without a worsening of 
neuropsychiatric symptoms.22,23 Another 
important perspective on management 
of difﬁcult behaviour in dementia comes 
from pain studies. Elderly persons in 
institutionalised care homes may experience 
a signiﬁcantly distressing amount of pain 
that goes unnoticed and untreated. One 
study found that only 15% of elderly persons 
who were in pain were given analgesics 
while another smaller study showed that 
‘difﬁcult’ elderly patients on antipsychotics 
were successfully managed with regular 
paracetamol dosing, and their behaviour did 
not regress on stopping the antipsychotics.24  
Conclusion
More than 9 out of every 10 dementia 
patients will experience at least one 
symptom of behavioural and psychological 
symptoms such as aggression and irritability, 
as well as relatively more subtle but 
common depressive symptoms.25 It seems 
clear that such symptoms are more common 
in patients with dementia than patients 
without dementia4, however it has been 
suggested that for a long time this aspect 
of dementia had not been given the 
attention it merits.26 Both pharmacological 
and non-pharmacological management of 
dementia have been the subject of many 
trials27 which have in turn been incorporated 
into clinical guidance. There is much to be 
done in the way of optimising the beneﬁts 
of treatments and reducing the risks of 
pharmacological and non-pharmacological 
management. Nevertheless, the evidence 
base for the management of behavioural 
and psychological symptoms in dementia is 
growing, allowing clinicians and researchers 
to continue improving global outcomes in 
dementia. 
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